The European Commission has granted Takeda Pharmaceutical (NYSE:TAK)
a Marketing Authorization for the subcutaneous (SC) formulation of
Entyvio (vedolizumab), a gut-selective biologic for use as maintenance
therapy in adults with moderately to severely active ulcerative colitis
(UC) or Crohn’s disease (CD).
Entyvio SC will be made available in both a pre-filled syringe and a pre-filled pen.
UC and CD are two of the most common forms of inflammatory bowel disease.
https://seekingalpha.com/news/3571985-takedas-subcutaneous-version-entyvio-okd-in-europe
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.